Loading...

EQ EQUILLIUM INC Investments/Divestments 8-K Filing

QLLM

Q

EQUILLIUM INC

(EQ)

2023 8-K

Show Summary

Show Summary

Noncompliance Notice

Equity Incentive Plan amend...

Financial Statements

Financial Results

Clinical Trial Results

Nasdaq Noncompliance

Q3 Financial Results

Itolizumab Update

Nasdaq Compliance

Financial Condition

Phase 2 Study Results

Annual Meeting of Stockholders

Financial Results Announcement

Positive Data from Phase 1b...

Financial Results Announcement

Appointment of Principal Ac...

Results of Operations and F...

Compliance Regained

EQ101 Phase 2 Study Enrollm...

Financial Results and Study...

Equillium Investor Day

Open Market Sale Agreement

Earnings Reports

Termination of Loan Agreement

Annual Meeting of Stockholders

Financial Results Announcement

Financial Results Announcement

External Links:

Equillium, Inc. has completed enrollment in its EQ101 Phase 2 study in alopecia areata, with topline data expected in Q2 2024. EQ302 will be advanced for potential treatment of gastrointestinal and skin diseases instead of EQ102.

AI Assistant

EQUILLIUM INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.